Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11515 | Pages: 139 | Charts: 50 | Tables: 38 |
The Malaysia nuclear medicine market was valued at $33.68 million in 2020, and is projected to reach $70.24 million by 2028, registering a CAGR of 9.86% from 2021 to 2028.
[COVIDIMPACTSTATEMENT]
Radiopharmaceuticals are formulations related to pharmaceuticals that include radioactive isotopes used in therapeutics and diagnosis. They are the simplest and among the smallest substances that contain radioactive substance. In addition, these can be used in the treatment of cancer, cardiac ailments & neurological disorders. Applications such as lymphoma and bone metastasis use radiopharmaceuticals, also known as nuclear medicines. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedure. In addition, nuclear medicines of modality, SPECT and PET work as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. More suitable therapeutic radiopharmaceuticals for oncology and cancer treatment replace the conventional chemotherapy methods to open up new opportunities in the radiopharmaceuticals market.
Get more information on this report : Request Sample Pages
Surge in the number of cancer cases in the Malaysian country and rise in awareness about nuclear medicine boost the growth of the market. However, convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include rise in incidence of cardiac patients and adoption of clear imaging techniques such as SPECT and PET in Malaysia, with the help of diagnostic equipment.
The factors that hinder the growth of the market include supply shortages, logistical difficulties, stringent regulations related to the use of nuclear medicine, and limited number of trained medical personnel.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe.
Nationwide lockdown, government regulations, and continuous increase in infection rate across the country created a widespread financial impact on neurology hospitals and clinics. There are a huge number of hospitals and clinics that have witnessed a drop in number of patient visits amid COVID-19 ultimately reducing client contact. Radiopharmaceuticals can be used for the detection of COVID-19. They have the potential to provide evidence and clarify contradictory concepts in the use of non-steroidal anti-inflammatory drugs for COVID-19 patients which is in the research phase. The resulting outcomes of the radiopharmaceuticals in the diagnosis of the COVID-19 infection are expected to help the market gain traction in the coming years. At the same time, limited availability of healthcare staff across the country is another factor, which has an undesirable effect on the Malaysia nuclear medicines market.
The Malaysia nuclear medicine market is segmented into type, modality, application, and end user. On the basis of type, the market is divided into diagnostics, therapeutics, and biochemistry research. By modality, the market is classified into SPECT, PET, beta emitters, alpha emitters, brachytherapy, and others. Furthermore, SPECT can be categorized into Technetium 99m, Chromium-51, Gallium-67 and others.
PET is further categorized into Fluorine 18, Gallium-68, and others. On the basis of application, the market is fragmented into oncology, cardiology, thyroid, neurology, and others. By end user, the nuclear medicine market is bifurcated into hospitals & diagnostic centers and research institutes.
By type, the diagnostics segment is the major revenue contributor, and is projected to grow at a significant rate during the forecast period. Surge in incidence of cardiac related ailments and better imaging technique with the help of diagnostic equipment such as SPECT and PET propel the market growth. The increase in number of cancer patients who require early diagnosis for appropriate treatment is the key factor that boost the growth of the segment.
[TYPEGRAPH]
Get more information on this report : Request Sample Pages
By modality, the SPECT segment is the major shareholder in the Malaysia nuclear medicines market, owing to surge in the market for medical diagnosis such as cardiology, cancer, and neurology. In addition, getting multiple 2-D and 3-D images that are found by performing SPECT imaging technique aids in receiving better access in visualization and is useful for the physicians.
By application, the oncology segment is expected to witness substantial market growth during the forecast period, owing to rise in advancements of radio-therapeutics which has propelled the ease in the treatment process of cancerous tumors and rise in the incidences of cancer.
[APPLICATIONGRAPH]
Get more information on this report : Request Sample Pages
By end user, the hospitals & diagnostic centers segment is expected to witness significant market growth during the forecast period, owing to surge in number of patient flow in the hospitals and the higher preference toward hospitals and diagnostic centers.
The key players profiled in this report include Cardinal Health, Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), GE Healthcare, Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), MERCK KGAA (Sigma Aldrich), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH), Siemens Healthcare GmbH, and Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp).
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidence of targeted population in Malaysia
3.5.1.2.Increase in population of geriatric population in Malaysia
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.2.Restraints
3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies in Malaysia
3.5.2.2.Short half-life of radiopharmaceuticals
3.5.3.Opportunity
3.5.3.1.Use of radiopharmaceuticals in neurological applications
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on Malaysia nuclear medicines Market
3.7.Cost estimation & return of Investment (Roi) for establishing A 30MEV cyclotron facility
CHAPTER 4:MALAYSIA NUCLEAR MEDICINE MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Diagnostics
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.3.Therapeutics
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.4.Biochemistry research
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
CHAPTER 5:MALAYSIA NUCLEAR MEDICINE MARKET, BY MODALITY
5.1.Overview
5.1.1.Market size and forecast
5.2.SPECT
5.2.1.Market size and forecast
5.3.PET
5.3.1.Market size and forecast
5.4.Beta emitters
5.4.1.Market size and forecast
5.5.Alpha emitters
5.5.1.Market size and forecast
5.6.Brachytherapy
5.6.1.Market size and forecast
5.7.Others
5.7.1.Market size and forecast
CHAPTER 6:MALAYSIA NUCLEAR MEDICINE MARKET, BY APPLICATION
6.1.Overview
6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast
6.2.Oncology
6.2.1.Market size and forecast
6.3.Cardiology
6.3.1.Market size and forecast
6.4.Thyroid
6.4.1.Market size and forecast
6.5.Neurology
6.5.1.Market size and forecast
6.6.Others
6.6.1.Market size and forecast
CHAPTER 7:MALAYSIA NUCLEAR MEDICINE MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospitals & diagnostic centers
7.2.1.Market size and forecast
7.3.Research Institutes
7.3.1.Market size and forecast
CHAPTER 8:COMPANY PROFILES
8.1.CARDINAL HEALTH, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.FUJIFILM HOLDINGS CORPORATION (IRVINE SCIENTIFIC SALES COMPANY, INC.)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.GE HEALTHCARE
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.ION BEAM APPLICATIONS (ION BEAM APPLICATIONS, SA)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.LANTHEUS HOLDINGS, INC. (LANTHEUS MEDICAL IMAGING, INC.)
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.MERCK KGAA (SIGMA ALDRICH)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.NOVARTIS AG (ADVANCED ACCELERATOR APPLICATIONS S.A.)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.OTSUKA HOLDING CO., LTD. (ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.SIEMENS HEALTHCARE GmbH
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TAIYO NIPPON SANSO CORPORATION (MITSUBISHI CHEMICAL HOLDINGS CORP)
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.COSTS OF ESTABLISHING A CYCLOTRON RADIOPHARMACEUTICAL PRODUCTION CENTRE
TABLE 02.MALAYSIA NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028($MILLION)
TABLE 03.MALAYSIA NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028($MILLION)
TABLE 04.MALAYSIA NUCLEAR MEDICINE MARKET FOR SPECT, 2020–2028 ($MILLION)
TABLE 05.MALAYSIA NUCLEAR MEDICINE MARKET FOR PET, 2020–2028 ($MILLION)
TABLE 06.MALAYSIA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028($MILLION)
TABLE 07.MALAYSIA NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028($MILLION)
TABLE 08.CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 09.CARDINAL HEALTH: OPERATING SEGMENT
TABLE 10.CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 11.FUJIFILM: COMPANY SNAPSHOT
TABLE 12.FUJIFILM: OERATING SEGMENT
TABLE 13.FUJIFILM : PRODUCT PORTFOLIO
TABLE 14.GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 15.GE HEALTHCARE: OERATING SEGMENT
TABLE 16.GE HEALTHCARE : PRODUCT PORTFOLIO
TABLE 17.IBA: COMPANY SNAPSHOT
TABLE 18.IBA: OPERATING SEGMENT
TABLE 19.IBA: PRODUCT PORTFOLIO
TABLE 20.IBA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 21.LANTHEUS: COMPANY SNAPSHOT
TABLE 22.LANTHEUS: OPERATING SEGMENTS
TABLE 23.LANTHEUS: PRODUCT PORTFOLIO
TABLE 24.MERCK: COMPANY SNAPSHOT
TABLE 25.MERCK: OPERATING SEGMENTS
TABLE 26.MERCK: PRODUCT PORTFOLIO
TABLE 27.NOVARTIS: COMPANY SNAPSHOT
TABLE 28.NOVARTIS: OERATING SEGMENT
TABLE 29.NOVARTIS : PRODUCT PORTFOLIO
TABLE 30.OTSUKA: COMPANY SNAPSHOT
TABLE 31.OTSUKA: OERATING SEGMENT
TABLE 32.OTSUKA : PRODUCT PORTFOLIO
TABLE 33.SIEMENS: COMPANY SNAPSHOT
TABLE 34.SIEMENS: OPERATING SEGMENTS
TABLE 35.SIEMENS: PRODUCT PORTFOLIO
TABLE 36.NIPPON SANSO: COMPANY SNAPSHOT
TABLE 37.NIPPON SANSO: OPERATING SEGMENT
TABLE 38.NIPPON SANSO: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.MALAYSIA NUCLEAR MEDICINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.LOW THREAT OF SUBSTITUTES
FIGURE 09.LOW THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.MALAYSIA NUCLEAR MEDICINE MARKET FOR DIAGNOSTICS, 2020–2028 ($MILLION)
FIGURE 14.MALAYSIA NUCLEAR MEDICINE MARKET FOR THERAPEUTICS, 2020–2028 ($MILLION)
FIGURE 15.MALAYSIA NUCLEAR MEDICINE MARKET FOR BIOCHEMISTRY RESEARCH, 2020–2028 ($MILLION)
FIGURE 16.MALAYSIA NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, 2020–2028 ($MILLION)
FIGURE 17.MALAYSIA NUCLEAR MEDICINE MARKET FOR ALPHA EMITTERS, 2020–2028 ($MILLION)
FIGURE 18.MALAYSIA NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY, 2020–2028 ($MILLION)
FIGURE 19.MALAYSIA NUCLEAR MEDICINE MARKET FOR OTHERS, 2020–2028 ($MILLION)
FIGURE 20.MALAYSIA NUCLEAR MEDICINE MARKET, BY ONCOLOGY, 2020–2028 ($MILLION)
FIGURE 21.MALAYSIA NUCLEAR MEDICINE MARKET, BY CARDIOLOGY, 2020–2028 ($MILLION)
FIGURE 22.MALAYSIA NUCLEAR MEDICINE MARKET, BY THYROID, 2020–2028 ($MILLION)
FIGURE 23.MALAYSIA NUCLEAR MEDICINE MARKET, BY NEUROLOGY, 2020–2028 ($MILLION)
FIGURE 24.MALAYSIA NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 25.MALAYSIA NUCLEAR MEDICINE MARKET, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2020–2028 ($MILLION)
FIGURE 26.MALAYSIA NUCLEAR MEDICINE MARKET, BY RESEARCH INSTITUTES, 2020–2028 ($MILLION)
FIGURE 27.CARDINAL HEALTH: NET SALES, 2018-2020 ($MILLION)
FIGURE 28.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.GE HEALTHCARE: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32.GE HEALTHCARE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 33.IBA: NET SALES, 2018-2020 ($MILLION)
FIGURE 34.IBA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.LANTHEUS: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.LANTHEUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.OTSUKA: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.OTSUKA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 46.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48.NIPPON SANSO: NET SALES, 2018-2020 ($MILLION)
FIGURE 49.NIPPON SANSO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.NIPPON SANSO: REVENUE SHARE BY REGION, 2020 (%)